Alipay+ Partners with Global Brands in #MoneyCannotBuy Initiative to Attract E-Wallet Users across Asia
29.9.2023 04:43:00 EEST | Business Wire | Press release
Alipay+ today launches the #MoneyCannotBuy marketing initiative, a series of social media campaigns and special rewards, as the provider of cross-border digital payments and marketing solutions teams with global merchants in bringing a unique travel experience to Asia’s e-wallet users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928554669/en/
With the debut treat unveiled in Dubai, a group of lucky e-wallet users would win round-trip flights in Dubai to find out the poems they submitted through an earlier Alipay+ social media campaign are projected onto the Burj Khalifa to light up the sky. (Photo: Business Wire)
#MoneyCannotBuy features major social media campaigns and special promotion from over 100 brands worldwide ranging from major theme parks to shopping malls, luxury retailers and major airports, for mobile-savvy travelers.
In China and beyond, travelers are seeking more memorable and unique travel experiences overseas. As part of the #MoneyCannotBuy campaign, Alipay+ is also hosting some 30 lucky e-wallet users from Malaysia, South Korea and Thailand on a Dream Tour, to share the excitement of the Asian Games and experience using their home e-wallets in China.
In-app offers for Alipay and other major e-wallet users
The initiative comes as Alipay+ has unveiled a series of special promotions for consumers globally, including Alipay users, for China’s longest public holiday, also known as Golden Week, which bridges over to fall and winter travel seasons.
On top of the #MoneyCannotBuy partner deals, Alipay users can also enjoy in-app car rental services across 200 countries and regions, extra 20% tax refund from major retailers in France, Italy and Spain, as well as other promotions offered by global merchants and tourism agencies.
Paralleled promotion and offers are also available to users of other Alipay+ partner e-wallets, including AlipayHK (Hong Kong SAR, China), GCash (The Philippines), TrueMoney (Thailand) and Touch ‘n Go eWallet among others. The offers range from coupons and free milk tea at Printemps in Paris to 10% off at Seoul's Noryangjin Fish Market.
2023 has been a year of major breakthroughs for Alipay+. Created as a suite of cross-border mobile payment and marketing solutions by Ant Group, Alipay+ now works with about 30 leading e-wallets. With its recent extension into the Chinese mainland, the service now connects tens of millions of merchants in 56 markets to over 1.4 billion payment accounts in Asia and beyond. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while travelling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
Alipay+ outbound tourism campaign this fall debuts in Dubai with Mid-Autumn rewards
As one of Chinese travelers’ new favorite destinations, Dubai’s downtown shopping malls, such as Galeries Lafayette, Bloomingdale's and Harvey Nichols, are rolling out 15-30% discounts to attract Chinese consumers. Alipay users can also enjoy perks like free massage from Galeries Lafayette when they book a session through the app.
A group of lucky e-wallet users from Alipay, AlipayHK (Hong Kong SAR China), Mpay (Macao SAR China) and OCBC (Singapore) even won round-trip flights and accommodation in Dubai. They also found the poems they submitted through an earlier Alipay+ social media campaign projected onto the 828-metre commanding Burj Khalifa to light up the sky.
The poems are presented alongside a 3-minute branding video of Alipay+ at the world’s tallest building in celebration of the Mid-Autumn Festival, a traditional festival of family and friends’ reunion under the full moon. The video showcases the importance of connectedness and heart-to-heart reunion through the lens of a rabbit traveling around the world in search of the moon.
The same branding video and poems will also be featured spontaneously at Aurora Plaza and Citibank Plaza on the Bund in Shanghai. For more fun, an underground train in Hangzhou has been revamped as a time tunnel to various hot destinations to mark the embarkment of the Golden Week and the #MoneyCannotBuy campaign.
“With a potential reach of over 1.4 billion consumers with increasing demand for unique travel and shopping experiences, we believe Alipay+ is in the best position to offer an omni-channel and pool resources with our merchants and digital payments partners,” said Dr Cherry Huang, General Manager of Alipay+ Offline Merchant Services at Ant Group. “We hope more businesses can take part in the initiative to help deliver the best #MoneyCannotBuy experiences to consumers and unleash more growth through innovation and collaboration.”
About Alipay+
Alipay+ is a suite of cross-border digital payment, marketing and digitalization solutions that help connect global merchants to consumers. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while travelling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230928554669/en/
Contact information
Media
Sarah Dai
Ant Group
Sarah.dai@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom